• Latest Posts

Could changing mRNA provide a new target for Alzheimer’s disease?

Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline

EMA accepts Marketing Authorization Application for lecanemab to treat early Alzheimer’s disease

JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases

Silo Pharma looks into the 2023 psychedelics crystal ball

ADVERTISEMENT

Lifesciences and biotech in 2023

Watch: Norway’s Pre Diagnostics looks to early detection of Alzheimer’s

‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward

bit.bio expands portfolio for drug discovery in neurodegenerative and neurological diseases

Interview 23 Nov 2022

What recent mixed clinical results can teach about Alzheimer’s disease

ADVERTISEMENT